Phase II Study of Sacituzumab Tirumotecan in Combination with Tagitanlimab for PD-L1–Positive, HR-Positive/HER2-Negative Advanced Breast Cancer Previously Treated with CDK4/6 Inhibitors (ChiCTR) - Oct 16, 2026 - P2 | N=35 | Recruiting | Sponsor: Sun Yat-sen University Cancer Center (Sun Yat-sen University Tumor Hospital, Sun Yat-sen University Institute of Oncology); Sun Yat-sen University Can
New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PD-L1
|